Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SECHIX:VLAP 64 3-1 Month Momentum % is -3.49% as of Aug. 02, 2026. GuruFocus rates CHIX:VLAP with a GF Score™ of 64/100 and a GF Value™ of €2.52 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,389 Biotechnology companies, Valneva SE ranks better than 59.54% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-02), Valneva SE's 3-1 Month Momentum % is -3.49%.
The industry rank for Valneva SE's 3-1 Month Momentum % or its related term are showing as below:
CHIX:VLAp's 3-1 Month Momentum % is ranked better than 59.54% of 1389
companies
in the Biotechnology industry
Industry Median: -7.65
vs CHIX:VLAp: -3.49
Valneva SE (CHIX:VLAp) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Valneva SE 3-1 Month Momentum % Related Terms
CHIX:VLAP vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Valneva SE's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Valneva SE's 3-1 Month Momentum % falls into.
Valneva SE (CHIX:VLAp) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (CHIX:VLAP) has a 3-1 Month Momentum % of -3.49% as of Aug. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Valneva SE and its competitors. According to the industry distribution chart, Valneva SE ranks #562 out of 1389 companies in the Biotechnology industry, placing it in the top 40.5%.
Is Valneva SE's 3-1 Month Momentum % too high?
Valneva SE's current 3-1 Month Momentum % is -3.49%. Based on the distribution chart, Valneva SE ranks #562 out of 1389 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Valneva SE has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #562 out of 1389 companies for 3-1 Month Momentum %. This puts Valneva SE in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Valneva SE and its competitors. Valneva SE's current 3-1 Month Momentum % is -3.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (CHIX:VLAP) is currently considered Fairly Valued. The stock's GF Value™ is €2.52, compared to a current price of €2.24 — trading 11.1% below its estimated fair value. The current 3-1 Month Momentum % is -3.49%. Valneva SE's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Valneva SE (CHIX:VLAP), the current 3-1 Month Momentum % is -3.49% as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (CHIX:VLAP) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of €2.24 is trading 11.1% below its estimated GF Value™ of €2.52.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for CHIX:VLAP:
3-1 Month Momentum %: -3.49%
GF Value™: €2.52 vs. price of €2.24 (11.1% below fair value)
No single metric tells the full story. See the CHIX:VLAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
64GF Score
Get the complete analysis for CHIX:VLAP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VLAP has been successfully added to your 
